Complement in cancer: Untangling an intricate relationship

Edimara S. Reis, Dimitrios C. Mastellos, Daniel Ricklin, Alberto Mantovani, John D. Lambris

Research output: Contribution to journalReview articlepeer-review

Abstract

In tumour immunology, complement has traditionally been considered as an adjunctive component that enhances the cytolytic effects of antibody-based immunotherapies, such as rituximab. Remarkably, research in the past decade has uncovered novel molecular mechanisms linking imbalanced complement activation in the tumour microenvironment with inflammation and suppression of antitumour immune responses. These findings have prompted new interest in manipulating the complement system for cancer therapy. This Review summarizes our current understanding of complement-mediated effector functions in the tumour microenvironment, focusing on how complement activation can act as a negative or positive regulator of tumorigenesis. It also offers insight into clinical aspects, including the feasibility of using complement biomarkers for cancer diagnosis and the use of complement inhibitors during cancer treatment.

Original languageEnglish
Pages (from-to)5-18
Number of pages14
JournalNature Reviews Immunology
Volume18
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

ASJC Scopus subject areas

  • Immunology

Fingerprint Dive into the research topics of 'Complement in cancer: Untangling an intricate relationship'. Together they form a unique fingerprint.

Cite this